| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Burroughs Amy L. | Chief Executive Officer, Director | C/O TERNS PHARMACEUTICALS, INC., 1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY | /s/ David Strauss, as Attorney-in-Fact for Amy L. Burroughs | 06 Jan 2026 | 0001872564 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TERN | Common Stock | Options Exercise | $99,997 | +21,551 | +56% | $4.64 | 60,315 | 02 Jan 2026 | Direct | |
| transaction | TERN | Common Stock | Options Exercise | +150,000 | +249% | 210,315 | 05 Jan 2026 | Direct | F1 | ||
| transaction | TERN | Common Stock | Sale | $2,718,230 | -71,339 | -34% | $38.10 | 138,976 | 05 Jan 2026 | Direct | F2, F3 |
| holding | TERN | Common Stock | 8,319 | 02 Jan 2026 | Trust | F4 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TERN | Stock Option (Right to Buy) | Options Exercise | $0 | -21,551 | -2% | $0.000000 | 1,053,449 | 02 Jan 2026 | Common Stock | 21,551 | $4.64 | Direct | F5 |
| transaction | TERN | Restricted Stock Unit | Options Exercise | $0 | -150,000 | -100% | $0.000000 | 0 | 05 Jan 2026 | Common Stock | 150,000 | Direct | F1, F6 |
| Id | Content |
|---|---|
| F1 | Each restricted stock unit represents the contingent right to receive, upon vesting, one share of common stock. |
| F2 | Represents shares of common stock sold to satisfy taxes associated with the vesting of a restricted stock unit award previously granted to the Reporting Person. Such sales do not represent a discretionary trade by the Reporting Person. |
| F3 | This sale price represents the weighted average sale price of the shares sold ranging from $37.43 to $39.595 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| F4 | The Reporting Person beneficially owns these shares indirectly through the Amy L Burroughs 2017 Trust. |
| F5 | 25% of the shares subject to the option vested on the first anniversary measured from January 1, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date. |
| F6 | The restricted stock unit award was granted on March 1, 2024. The restricted stock unit award was subject to vesting as to 50% of the shares underlying the award if the average closing price of the Issuer's common stock over 30 consecutive trading days equaled or exceeded $15.00 per share and as to the remaining 50% of the shares underlying the award if the average closing price of the Issuer's common stock over 30 consecutive trading days equaled or exceeded $20.00 per share. The performance criteria for the specified milestones were determined to have been achieved by the Compensation Committee as to 100% of the underlying shares, and the delivery and release of the underlying shares occurred on January 5, 2026. |